Join other medical, science, and publications professionals worldwide to #PressforProgress on #IWD2018 and beyond.
The FDAAA 2007 requires clinical trials to make results publicly available 12 months after study completion. A new tool from TrialsTracker provides a live online report on compliance.
Missed ISMPP EU 2018? Read our meeting report to get up to speed!
Online Registration Until January 3, 2018! Medical publication professionals from the pharmaceutical industry, medical communication agencies, journals, academia, etc., are all welcome to participate in the 2018 European Meeting of … Continue Reading Calling All Medical Publication Professionals – Join Us at the 2018 European ISMPP Meeting
Although most scientists understand the importance of publishing all study data, it remains a fact that articles describing data that do not confirm the author’s hypothesis are less likely to … Continue Reading Celebrating the positives in negative results
Recently, F1000Research published the first article of their new Registered Report initiative. The publisher is the first to go a step further with this publication format, combining the Registered Report … Continue Reading Registered Reports: enhancing transparency and reproducibility in scientific publication
In a position paper published in The Leadership Quarterly earlier this year, Professor John Antonakis described factors that he believes are stifling the production of useful scientific research. In response to … Continue Reading ‘Bad science’ and how new ideas in scientific publishing can combat it
Over two days last month (17-18 January, 2017), around 250 delegates and exhibitors attended the 2017 European meeting of the International Society for Medical Publication Professionals (ISMPP) in London. The … Continue Reading Meeting report: Summary of Day 2 of the 2017 European #ISMPP Meeting
It has been suggested that a sizeable number of registered clinical trials fail to report their results, and that negative or null results are especially likely to remain unpublished. To help tackle … Continue Reading TrialsTracker attempts to identify trials with potentially unreported results
Making all clinical data, regardless of outcome, available to the public is one of the edicts of The World Health Organization and is a key factor in the drive for … Continue Reading Citation rate of clinical studies is skewed towards positive outcomes
In a recent article published in the Royal Society Open Science journal, Paul E. Smaldino and Richard McElreath describe the destructive and self-perpetuating cycle of “bad science”. The authors compare … Continue Reading The perpetuating cycle of “bad science”
Accurate reporting of data is an essential part of the research process. However, the misreporting of results in biomedical research publications, whether intentional or otherwise, can and does occur. This … Continue Reading Inappropriate image duplication found in 1 in 25 publications
Clinical trial data is often utilised for the purposes of clinical and health policy decision-making, with journal publications and registry reports the main sources for this information. Therefore, it is … Continue Reading Insufficient harms reporting: journal publications vs clinical study reports
As a prerequisite for publication of research, the International Committee of Medical Journal Editors (ICMJE) requires registration of clinical trials and recommends this to editors of medical journals. Similarly, provision … Continue Reading Retrospective vs. prospective registration of clinical trials – what is the norm?
Clinical trials with negative results have traditionally been viewed as ‘failures’. However, in the current age of transparency, there is a strong movement to ensure that all data, positive or negative … Continue Reading Phase III cancer clinical trials: the positive side of negative results
It is established best-practice that all clinical trial outcomes should be pre-specified in a trial protocol and on a clinical trial registry and then reported once the trial is complete. … Continue Reading Fixing the problem of outcome-switching in clinical trials